KalVista, awaiting FDA call on HAE drug, sells Japanese rights to Kaken in $22M deal
As KalVista Pharmaceuticals awaits an FDA decision on sebetralstat, the company has sold the Japanese rights to Kaken for $11 million upfront.
As KalVista Pharmaceuticals awaits an FDA decision on sebetralstat, the company has sold the Japanese rights to Kaken for $11 million upfront.
